KZIA Leading Diagonal Wave 5 begins

Hello,

What is KZIA?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is headquartered in Sydney, Australia.

News

My Thoughts For You
Click on the link "News" and you will find that the outcome is showing positive results which will affect the price.

Good Luck, Cheers!

Be sure to comment, follow, like, and check out my profile for more trade ideas!
Technical IndicatorsTrend AnalysisWave Analysis

更多:

相關出版品

免責聲明